Human CD153 / CD30L / TNFSF8 Protein (Fc Tag)

Catalog Number: **10040-H01H**

Sino Biological Inc.
Biological Solution Specialist

General Information

Gene Name Synonym:

TNFSF8, CD153, CD30L, CD30LG, MGC138144

Protein Construction:

A DNA sequence encoding the extracellular domain (Gln 63-Asp 234) of human CD30 Ligand (NP_001235.1) was fused with the Fc region of human IgG1 at the N-terminus.

Source: Human

Expression Host: Human Cells

QC Testing

Purity: > 95 % as determined by SDS-PAGE

Bio-Activity

Measured by its binding ability in a functional ELISA . Immobilized recombinant human CD30L at 20 μg/ml (100 μl/well) can bind biotinylated human CD30 with a linear range of 0.31-20 ng/ml .

Endotoxin:

< 1.0 EU per μg of the protein as determined by the LAL method

Stability:

Samples are stable for up to twelve months from date of receipt at -70 ℃

Predicted N terminal: Arg 23

Molecular Mass:

The recombinant human Fc/CD30L is a disulfide-linked homodimeric protein. The reduced monomer consists of 429 amino acids and has a predicted molecular mass of 47.8 kDa. As a result of glycosylation, the apparent molecular mass of rh Fc/CD30L monomer is approximately 60-65 kDa in SDS-PAGE under reducing conditions.

Formulation:

Lyophilized from sterile PBS, pH 7.4

Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

Usage Guide

Storage:

Store it under sterile conditions at -20℃ to -80℃ upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage.

Avoid repeated freeze-thaw cycles.

SDS-PAGE:



Reconstitution:

Detailed reconstitutio ı the products.

Protein Descri

CD30 ligand (CD30L), also known as CD153 and TNFSF8, is a cytokine belonging to the emerging tumor necrosis factor (TNF) ligand superfamily, and is a specific ligand for CD30/ TNFRSF8 originally described as a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. CD30L is a type-II membrane glycoprotein expressed on activated T cells, stimulated monocyte-macrophages, granulocytes, eosinophils, and some Burkitt-like lymphoma cell lines. CD30L is capable of transducing signals through CD30 on different CD30+ lymphoma cell lines, and mediates pleiotropic biologic effects including cell proliferation, activation, differentiation, as well as cell death by apoptosis. CD30-CD30 ligand interaction has been suggested to have a pathophysiologic role in malignant lymphomas, particularly Hodgkin disease, large cell anaplastic lymphomas and Burkitt lymphomas, and is also involved in activation and functioning of the T cell-dependent immune response.

References

1. Gruss,H.J.et al.,1994, Blood. 83: 2045-2056.6: 1521-1529.
2. Croager,E.J. et al., 1997, Biochim. Biophys. Acta 1353: 231-235.
3. Wendtner, C.M. et al., 1995, Cancer. Res. 55: 4157-4161.
4. Fischer,M. et al., 2006, J. Clin. Invest. 116: 2748-2756
5. Blazar, B.R. et al., 2004, J.Immunol. 173: 2933-2941.